First proprietary pipeline targeting ischemic acute kidney failure
First written in FY2025-H1. 6 of 7 entries say "Advanced", first in 2026-03-02. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「In our independent efforts to create new mRNA-targeted drugs, or to create an in-house pipeline, we prepared for animal studies toward conducting preclinical testing of a drug-candidate substance for which a substance patent had already been applied for, in Pipeline 1, an ASO-based disease-treatment project targeting ischemic acute kidney injury caused by cardiovascular surgery.」
For the first in-house pipeline, the p53 ASO targeting ischemic acute kidney injury, the company advanced to the stage of preparing animal studies for preclinical testing using a candidate substance for which a substance patent application had been filed. - FY2025AdvancedAnnual report
「Our most advanced project is an ASO targeting p53. Because we obtained a compound with higher activity than the substance for which a patent had already been granted, we filed an additional patent application in December 2025 and designated it as our first pipeline. The target disease for this pipeline is the prevention of ischemic kidney disease during cardiac surgery, and research and development are continuing. We estimate that, if approved and commercialized, this drug could generate domestic annual sales of approximately ¥15 billion.」
For the first in-house pipeline, the p53 ASO, the company obtained a higher-activity compound than the previously patented substance and filed an additional substance patent application in December 2025. It continues research and development targeting the prevention of ischemic kidney disease. - 2026-03-02AdvancedGeneral Meetings of Shareholders
「The project progressed smoothly, and in December we filed a patent application for the ASO resulting from the research.」
For the first in-house pipeline targeting ischemic acute kidney injury, a patent application based on the research results represented concrete progress. - FY2025-H1First statedAnnual report
「During the interim accounting period, we designated ischemic acute kidney injury caused by cardiovascular surgery as the disease target for our drug-discovery research and decided to pursue it as our first pipeline.」
For future business diversification, the company designated ischemic acute kidney injury occurring after cardiovascular surgery as the disease target for its first in-house pipeline, making this policy explicit for the first time.